Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Stocks to Buy with Exponential Growth Heading into 2026. On October 20, the company released its financial results and gave an update on operational progress for Q3 2025. Summit Therapeutics Inc. (NASDAQ:SMMT) announced that, on the basis of the results of HARMONi clinical trial, it is planning to submit a Biologics License Application (BLA) to seek approval for ivonescimab plus chemotherapy for the proposed indication. Notably, the company plans to subm ...